ANGO logo

ANGO
Angiodynamic Inc

1,063
Mkt Cap
$440.83M
Volume
260,680.00
52W High
$13.99
52W Low
$8.36
PE Ratio
-15.75
ANGO Fundamentals
Price
$10.60
Prev Close
$10.71
Open
$10.78
50D MA
$10.88
Beta
1.06
Avg. Volume
390,242.71
EPS (Annual)
-$0.8321
P/B
2.50
Rev/Employee
$433,330.37
$364.75
Loading...
Loading...
News
all
press releases
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
ANGO stock is buoyed by strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer and broad Med Tech growth supporting margins.
Zacks·3d ago
News Placeholder
More News
News Placeholder
AngioDynamics CEO Details Portfolio Shift as Auryon, AlphaVac and NanoKnife Fuel Growth at Conference
AngioDynamics (NASDAQ:ANGO) CEO Jim Clemmer said the company has spent the last several years reshaping its portfolio and operating model, moving away from slower-growth, more commodity-oriented...
MarketBeat·5d ago
News Placeholder
Veeva Systems' Stock Up After Q4 Earnings & Revenues Beat Estimates
VEEV beats Q4 estimates with 16% revenue growth and strong subscription demand, while an upbeat FY27 outlook and expanding AI capabilities push shares higher.
Zacks·9d ago
News Placeholder
RGTI Stock Down Despite Q4 Earnings Top Estimates, Revenues Decline Y/Y
Rigetti beats earnings estimates in Q4 with a narrower loss, but revenue declines year over year and margins contract amid higher operating expenses.
Zacks·9d ago
News Placeholder
Short Interest in AngioDynamics, Inc. (NASDAQ:ANGO) Decreases By 17.6%
AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) saw a significant drop in short interest in February. As of February 13th, there was short interest totaling 1,699,336 shares, a drop of 17.6% from...
MarketBeat·11d ago
News Placeholder
Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus
Contineum Therapeutics surged 27% after a Zacks Rank upgrade, spotlighting how Zacks' strategies are beating a volatile market.
Zacks·12d ago
News Placeholder
Clover Health Q4 Earnings Meet Estimates, Sales Beat, Membership Rises
CLOV Q4 loss matches estimates. Revenues jump 45%. The 2026 outlook calls for up to 49% growth and potential GAAP profitability.
Zacks·15d ago
News Placeholder
XRAY Stock Gains Despite Q4 Earnings Miss on Restructuring Initiative
XRAY climbs nearly 8% pre-market as it unveils a $120M restructuring plan, even after Q4 earnings miss and softer 2026 outlook.
Zacks·15d ago
News Placeholder
TMDX Stock Rises as Q4 Earnings & Revenues Beat Estimates
TransMedics posts 200% EPS surge and 32% revenue growth in Q4, tops estimates and guides for up to 25% sales growth in 2026.
Zacks·17d ago
News Placeholder
AngioDynamics to Present at the Leerink Partners Global Healthcare Conference
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options...
Business Wire·19d ago
<
1
2
...
>

Latest ANGO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.